OTC Manufacturers Less Likely To Face Inspection Under cGMP Pilot
This article was originally published in The Tan Sheet
Executive Summary
Manufacturing facilities that produce OTC drugs exclusively may not be inspected as often as plants that make prescription drugs under FDA's risk-based prioritization plan for inspections
You may also be interested in...
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth